Skip to main content
TipRanks
Go Ultimate75% OFF

Lakefront Biotherapeutics NV (GXE) Stock Forecast & Price Target

6 Followers
See the Price Targets and Ratings of:

GXE Analyst Ratings

Moderate Sell
2Ratings
0Buy1Hold1Sell
Based on 2 analysts giving stock ratings to Lakefront Biotherapeutics NV in the past 3 months

GXE Stock 12 Month Forecast

€24.95▼(-16.89% Downside)
Based on 2 Wall Street analysts offering 12 month price targets for Lakefront Biotherapeutics NV in the last 3 months. The average price target is EUR 24.95 with a high forecast of EUR 27.90 and a low forecast of EUR 22.00. The average price target represents a -16.89% change from the last price of EUR 30.02.
Highest Price Target€27.90Average Price Target€24.95Lowest Price Target€22.00

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:GXE
Price TargetArticle
Barclays€22sell-26.72%DownsideReiterated09/08/26
Bernstein€27.90hold-7.06%DownsideReiterated09/01/26
Kepler Capital €23.50sell-21.72%DownsideReiterated05/07/26
UBS€30hold-0.07%DownsideReiterated04/01/26
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lakefront Biotherapeutics NV

3 Months
Christophe dombu
Christophe dombuKepler Capital
Success Rate6/12 ratings generated profit
50%
Average Return
-2.89%

Copying Christophe dombu's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -2.89% per trade.

1 Year
Christophe dombu
Christophe dombuKepler Capital
Success Rate3/12 ratings generated profit
25%
Average Return
-6.93%

Copying Christophe dombu's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -6.93% per trade.

2 Years
Christophe dombu
Christophe dombuKepler Capital
Success Rate2/12 ratings generated profit
17%
Average Return
-18.13%

Copying Christophe dombu's trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -18.13% per trade.

GXE Analyst Recommendation Trends

02468Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for GXE
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy00000
Buy00000
Hold00111
Sell21221
Strong Sell00000
total21332

In the current month, GXE has received 0 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. GXE average Analyst price target in the past 3 months is 24.95.

GXE Financial Forecast

€-3€0.75€4.5€8.25€12Q1 2026Q3 2026Q4 2026
High€-0.01
Consensus€-0.66
Low€-1.70

GXE Earnings Forecast

Next quarter’s earnings estimate for GXE is -EUR 0.66 with a range of -EUR 1.70 to -EUR 0.01. The previous quarter’s EPS was -EUR 0.04. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.

€849,999€225.8M€450.8M€675.8M€900.8MQ1 2026Q3 2026Q4 2026
High€12M
Consensus€7.19M
Low€850K

GXE Sales Forecast

Next quarter’s sales forecast for GXE is EUR 7.19M with a range of EUR 850.00K to EUR 12.00M. The previous quarter’s sales results were EUR 7.58M. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.

GXE Stock Forecast FAQ

What is DE:GXE’s average 12-month price target, according to analysts?
Based on analyst ratings, Lakefront Biotherapeutics NV’s 12-month average price target is €24.95.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Lakefront Biotherapeutics NV a Buy, Sell or Hold?
Lakefront Biotherapeutics NV has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 1 hold ratings and 1 sell ratings.
What is Lakefront Biotherapeutics NV’s share price target?
The average share price target for Lakefront Biotherapeutics NV is €24.95. This is based on 2 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €27.90, and the lowest forecast is €22.00. The average share price target represents a 16.89% decrease from the current price of €30.02.
What do analysts say about Lakefront Biotherapeutics NV?
Lakefront Biotherapeutics NV’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 2 Wall Street analysts.
How can I buy shares of Lakefront Biotherapeutics NV?
To buy shares of DE:GXE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.